Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Yung

Showing results (191-200 of 217) with videos related to

Pageof 22
Sort By:
Neuro-Oncology|March 22, 2008
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomasKathleen R Lamborn, W K Alfred Yung, Susan M Chang, et al.
Oncoimmunology|July 30, 2016
Prioritization schema for immunotherapy clinical trials in glioblastomaTiffany R Hodges, Sherise D Ferguson, Hillary G Caruso, et al.
Neuro-Oncology|January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.
Neuro-Oncology|April 6, 2021
Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experienceEudocia Q Lee, Wendy Selig, Clair Meehan, et al.
Neuro-Oncology|March 19, 2009
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2018
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant GliomaFrederick F Lang, Charles Conrad, Candelaria Gomez-Manzano, et al.
Neuro-Oncology|August 29, 2014
Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working GroupBrian M Alexander, Evanthia Galanis, W K Alfred Yung, et al.
Cancer Cell|September 13, 2011
An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymomaJennifer M Atkinson, Anang A Shelat, Angel Montero Carcaboso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2012
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03Eudocia Q Lee, Vinay K Puduvalli, Joel M Reid, et al.
Neuro-Oncology|April 5, 2022
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumorsBenjamin M Ellingson, Elizabeth R Gerstner, Andrew B Lassman, et al.
Pageof 22

Showing results (191-200 of 217) with videos related to

Sort By:
Pageof 22
Neuro-Oncology|March 22, 2008
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomasKathleen R Lamborn, W K Alfred Yung, Susan M Chang, et al.
Oncoimmunology|July 30, 2016
Prioritization schema for immunotherapy clinical trials in glioblastomaTiffany R Hodges, Sherise D Ferguson, Hillary G Caruso, et al.
Neuro-Oncology|January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.
Neuro-Oncology|April 6, 2021
Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experienceEudocia Q Lee, Wendy Selig, Clair Meehan, et al.
Neuro-Oncology|March 19, 2009
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2018
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant GliomaFrederick F Lang, Charles Conrad, Candelaria Gomez-Manzano, et al.
Neuro-Oncology|August 29, 2014
Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working GroupBrian M Alexander, Evanthia Galanis, W K Alfred Yung, et al.
Cancer Cell|September 13, 2011
An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymomaJennifer M Atkinson, Anang A Shelat, Angel Montero Carcaboso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2012
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03Eudocia Q Lee, Vinay K Puduvalli, Joel M Reid, et al.
Neuro-Oncology|April 5, 2022
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumorsBenjamin M Ellingson, Elizabeth R Gerstner, Andrew B Lassman, et al.
Pageof 22